Navigation Links
Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
Date:8/22/2013

development-and-worldwide-license-agreement-for-investigational-anti-cancer-drug-pci-32765">December 2011 to co-develop and co-commercialize ibrutinib.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our futu
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
4. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
5. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
6. Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013
7. Physicians Expect More Out of Tablet-Toting Pharmaceutical Sales Reps, Study Finds
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
10. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
11. Recent Study Reveals Physicians Prefer Topical Delivery for Drug Delivery Technology, Such as a Transdermal Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Rock Creek Pharmaceuticals, Inc. (NASDAQ: ... that the Food and Drug Administration ("FDA"), has notified ... RCP,s Investigational New Drug ("IND") application before granting the ... US. Dr. Chris Chapman , RCP,s ... on our IND. When we receive the agency,s official ...
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... . , April 30 A new study, presented at ... , found that Breast-Specific Gamma Imaging (BSGI) is highly accurate in monitoring ... , , ... has been proven in several other studies to improve breast cancer detection ...
... April 29 Warner Chilcott plc (Nasdaq: WCRX ) announced ... market opening on Friday, May 7, 2010 . , ... In addition to issuing a press release, the Company will host a ... 8:00 AM (Eastern Time) to review the results. To participate in the ...
Cached Medicine Technology:BSGI Offers Clear View of Breast Tumor Response to Neoadjuvant Chemotherapy 2Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results 2
(Date:7/13/2014)... The report “Micronutrient Market by Type (Zinc, ... Non Chelated), Application Mode (Soil, Foliar, Fertigation), Crop ... to 2018” defines and segments the global agriculture ... the global value and volume for agriculture micronutrients. ... for the global agriculture micronutrients market with an ...
(Date:7/13/2014)... 13, 2014 MarketsandMarkets recently conducted ... Modeling; 3D Scanning; 3D rendering; Layout and Animation; ... (2013 - 2018)”, which analyzes and studies the ... America, Western Europe, Eastern Europe, Middle East and ... draws the competitive landscape of the 3D imaging ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
(Date:7/13/2014)... July 13, 2014 Recently, MyDressCity.com, one ... women’s special occasion outfits, has released its new range ... the new products are available at discounted prices. Worldwide ... 2014. , In the company’s online shop, there ... of them are made with great materials. MyDressCity.com’s hot ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... KR ) said today,it is recalling Private Selection Peanut ... butter in the ice cream was supplied by,Peanut Corporation of ... following names are included in this recall: City Market, ... Stores the company operates under the following names ...
... factors are just as reliable, researchers say, , , MONDAY, ... variation is associated with an increased risk for heart ... who is likely to get heart disease any more ... , There has been continuing excitement in recent years ...
... early-stage lung cancer are not seen when patients are ... January issue of Archives of Surgery , one ... deaths in the United States than any other cancer, ... surgery to remove a portion of the lungprovides the ...
... received recommended care did better, regardless of race, study ... disparities between white and black patients with early-stage lung ... to a U.S. study that included nearly 18,000 patients. ... lung (pulmonary resection) provides the best chance of a ...
... of blood pressure, other factors may be boosting survival, ... First-time heart attacks in the United States aren,t as ... a long-running study finds. , "We know that deaths ... Meyerson, director of the cardiovascular disease prevention program at ...
... specializing in healthcare services at Affiliated Computer Services, Inc. ... highest ranking in a national survey for the second ... place award for its work in the Financial Enterprise ... Top 20 Best in KLAS Awards: Software & Professional ...
Cached Medicine News:Health News:Kroger Recalls Select Ice Cream Products Due to Possible Health Risk 2Health News:Genetic Data May Not Boost Heart Disease Predictions 2Health News:Study examines racial disparities in survival among patients diagnosed with lung cancer 2Health News:Optimal Treatment Boosts Blacks' Lung Cancer Survival 2Health News:U.S. Heart Attacks Becoming Less Severe 2Health News:U.S. Heart Attacks Becoming Less Severe 3Health News:ACS is 'Best in KLAS' for Healthcare Financial Implementation Services for Second Consecutive Year 2Health News:ACS is 'Best in KLAS' for Healthcare Financial Implementation Services for Second Consecutive Year 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: